P21: Mechanistic Overview
internal_protocol · preclinical · status: needs_provider_review
Metadata
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
Embedding: pending
File: signed link
Summary (generated — provider review required)
P21 (P021) is a neurotrophic peptide derived from a CNTF fragment, studied preclinically for neurogenesis and cognition. Mechanism: reported BDNF pathway activation and reduction of tau pathology in animal models. Relevance: neurocognitive and neuroinflammatory contexts.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (3) · phenotypes (0)
evidence_reference, safety_reference, dosing_reference
Evidence claims (3) · review items (2)
outcome · pending
Mechanism: reported BDNF pathway activation and reduction of tau pathology in animal models.
safety · pending
Safety: preclinical only; no established human data.
dosing · pending
Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.
Extracted chunks (1)
56 approx tokens across 1 chunks.